Jiajun W. Fu
Ganzhou, 341000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2.
Journal: Journal of lipid research
Published: January 21, 2025
Multispecies transcriptomics identifies SIKE as a MAPK repressor that prevents NASH progression.
Journal: Science translational medicine
Published: February 14, 2024
Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction-associated steatohepatitis.
Journal: The Journal of clinical investigation
Published: June 20, 2023
Efficacy and predictive factors of glucocorticoid therapy for patients with hepatitis B virus-related acute-on-chronic liver failure.
Journal: Acta gastro-enterologica Belgica
Published: December 25, 2022
TRIM56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase.
Journal: The Journal of clinical investigation
Published: October 10, 2022
Switch-associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1.
Journal: Hepatology (Baltimore, Md.)
Published: June 14, 2021
A conventional immune regulator mitochondrial antiviral signaling protein blocks hepatic steatosis by maintaining mitochondrial homeostasis.
Journal: Hepatology (Baltimore, Md.)
Published: February 22, 2021
TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury.
Journal: Hepatology (Baltimore, Md.)
Published: February 12, 2021
Last Updated: 09/26/2026